| Literature DB >> 33374507 |
Joanna Jarosz-Popek1, Marta Wolska1, Aleksandra Gasecka2, Pamela Czajka1, Daniel Jakubik1, Lucia Sharif1, Taqwa Adem1, Wei-Ling Liu1, Dagmara Mirowska-Guzel1, Marek Postula1, Ceren Eyileten1.
Abstract
Diabetes mellitus (DM) is a complex condition and serious health problem, with growing occurrence of DM-associated complications occurring globally. Persistent hyperglycemia is confirmed as promoting neurovascular dysfunction leading to irreversible endothelial cell dysfunction, increased neuronal cell apoptosis, oxidative stress and inflammation. These collaboratively and individually result in micro- and macroangiopathy as well as neuropathy demonstrated by progressive neuronal loss. Recently, major efforts have been pursued to select not only useful diagnostic and prognostic biomarkers, but also novel therapeutic approaches. Both microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) belong to a class of non-coding RNAs identified in most of the body fluids i.e., peripheral blood, cerebrospinal fluid, brain tissue and neurons. Numerous miRNAs, lncRNAs and their target genes are able to modulate signaling pathways known to play a role in the pathophysiology of progressive neuronal dysfunction. Therefore, they pose as promising biomarkers and treatment for the vast majority of neurodegenerative disorders. This review provides an overall assessment of both miRNAs' and lncRNAs' utility in decelerating progressive nervous system impairment, including neurodegeneration in diabetic pathways.Entities:
Keywords: biomarker; lncRNA; miR; miRNA; non-coding RNA; novel biomarker; treatment
Year: 2020 PMID: 33374507 DOI: 10.3390/jcm10010009
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241